Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
DeviceContinuous Glucose Monitoring and frequent sample testing
NCT Number: NCT03966911
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
Looking for future studies?
Notify Me2 year–80 year
All sexes
Interventional
Not applicable
AMCR Institue, Escondido, California, United States
The study is a multi-center, prospective, single-sample correlational design without controls. The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Continuous Glucose Monitoring and frequent sample testing
Time frame: 7 days (170 hours)
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values < 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.
Medtronic MiniMed, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07696039
Autoimmune Diseases, Diabetes Mellitus
Bergamo, Italy
View Trial DetailsNCT03263494
Autoimmune Diseases, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT07090824
Autoimmune Diseases, Diabetes Mellitus
Palo Alto, California, United States
View Trial DetailsNCT05211479
Adolescent, Anxiety Disorders
Yalova, Turkey (Türkiye)
View Trial Details